Clinical trials: Neutralizing Antibody
Nephropathy, Opportunistic Viral Infection
Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy
The aim of this observational study is to characterize the urinary replication of BK polyomavirus (BKV) in kidney transplant recipients.
- Conditions
- Nephropathy, Opportunistic Viral Infection, Polyoma Virus Nephropathy, BK Nephropathy
- Trial name
- TYPIK (NCT07347769)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Cystic Fibrosis, Neutralizing Antibodies
Characterization of Antibacterial Antibodies in Patients With Cystic Fibrosis
Most of the cystic fibrosis (CF) patients are or have been pulmonary colonized with bacteria such as Pseudomonas aeruginosa or Staphylococcus aureus.
- Trial name
- NCT04700358
- Testing
- Blood sampling
- Where
- Germany
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital of Cologne
HIV-1 Infection, Neutralizing Antibody
VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...
This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclonal antibody. VRC01 is a broadly neutralizing antibody directed against HIV.
- Conditions
- HIV-1 Infection, Neutralizing Antibody, Monoclonal Antibody, Viral Load
- Trial name
- NCT01950325
- Testing
- VRC-HIVMAB060-00-AB
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Monoclonal Antibody, Human
Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
Background: VRC01 is a manmade antibody directed against the human immunodeficiency virus (HIV). Antibodies fight infection. Researchers eventually want to know if VRC01 helps prevent or treat HIV infection.
- Conditions
- HIV Infection, Monoclonal Antibody, Human, HIV Antibodies, VRC01 Monoclonal Antibody
- Trial name
- NCT01993706
- Testing
- VRC-HIVMAB060-00-AB
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of HIV Infection, HIV Antibodies
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
Background: Antibodies help the body fight infection. VRC01LS is an antibody directed against HIV virus. HIV attacks the immune system. In animals, VRC01LS inactivated many types of HIV viruses.
- Conditions
- Prevention of HIV Infection, HIV Antibodies, Monoclonal Antibody, Human, Neutralizing Antibody
- Trial name
- NCT02599896
- Testing
- VRC-HIVMAB080-00-AB (VRC01LS), VRC-HIVMAB060-00-AB (VRC01)
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)